SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)

Exclusion Criteria

• •1. Previous and known symptomatic CHF, from class II to IV (included)
• •2. History of CABG (Coronary Artery Bypass Surgery) surgery
• •3. History of former significant mitral valve replacement surgery or heart transplantation.
• •4. Severe valve disease: mitral, aortic stenosis / insufficiency.
• •5. Diagnosis of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis
• •6. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter access to LV
• •7. Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive device.
• •8. Documented presence of a known LV thrombus
• •9. Sepsis
• •10. Endocarditis
• •11. Infectious pericarditis
• •12. Pericardial tamponade
• •13. Left ventricular aneurysm, collagen tissue disease
• •14. Severe peripheral vascular disease precluding femoral artery access as determined at the time of original catheterization.
• •15. Pacemaker, implantable cardiac defibrillator, and intra-cerebral aneurysm clips.
• •16. History of metallic foreign body in their eye
• •17. Former or current aortic dissection
• •18. Inadequate bone marrow function: Haemoglobin \< 10 g/dL and Platelet count \< 100 x 109 / L
• •19. Previous G-CSF or other Hematopoietic Growth Factor administrations.
• •20. Blood transfusion(s) within the previous 4 weeks (to exclude potential non-autologous ACPs (Angiogenic Cells Precursors) in the harvested blood).
• •21. Hepatic failure or history of liver cirrhosis or hepatic severe impairment.
• •22. Constitutional or acquired coagulopathy
• •23. Treated chronic renal failure, or haemodialysis or renal severe impairment (creatinine clearance \< 30ml/min).
• •24. Prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in complete response without any treatment in the last 5 years.
• •25. History of prior mediastinal radiation exposure
• •26. Serious underlying medical conditions at the investigator's discretion, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple Sclerosis).
• •27. Chronic immunomodulatory or cytotoxic drug treatment intake.
• •28. Active bleeding or major surgery within 1 month.
• •29. Human immunodeficiency HIV1-2, HTLV1, HTLV2
• •30. History or current Hepatitis B (prior vaccination accepted)
• •31. History or current Hepatitis C
• •32. Syphilis
• •33. Chronic Obstructive Pulmonary Disease.
• •34. Active participation in any other clinical trials
• •35. Current or recent treatment (within the 60 days period before PTCA and stent(s) implantation) with another investigational drug or procedure.
• •36. Any other co-existing conditions that will preclude participation in the study or compromise ability to give informed consent.
• •37. Requirement of i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) initiated 24 hours before cMRI.
• •38. Splenomegaly
• •39. Phenylketonuria
• •40. History of iron-Dextran allergy
• •41. History of murin protein allergy